SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. The company was incorporated in 2011 and is based in Rolle, Switzerland.
Financial Outlook | Analyst price targets range from $5 to $7, with expectations of double-digit revenue growth in 2025 as new offerings gain traction |
Strategic Initiatives | Learn about SOPHiA's cost reduction efforts, product development plans, and market diversification strategies aimed at driving long-term growth |
Market Dynamics | Explore the company's navigation of biopharma sector headwinds and regional softness, while maintaining strong performance in the U.S. market |
Data-Driven Growth | SOPHiA GENETICS expands its customer base, adding 20 new clients and achieving 17% year-over-year volume growth, despite sector challenges |
Metrics to compare | SOPH | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSOPHPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.6x | −8.0x | −0.5x | |
PEG Ratio | 0.19 | −0.02 | 0.00 | |
Price / Book | 7.7x | 0.5x | 2.6x | |
Price / LTM Sales | 4.7x | 0.6x | 3.2x | |
Upside (Analyst Target) | 41.1% | 51.3% | 45.7% | |
Fair Value Upside | Unlock | 26.1% | 4.8% | Unlock |